益气疏风汤联合盐酸西替利嗪片治疗慢性荨麻疹临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R758.24

基金项目:


Clinical Study on Yiqi Shufeng Tang Combined with Cetirizine Hydrochloride Tablets for Chronic Urticaria
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察益气疏风汤联合盐酸西替利嗪片治疗血虚风燥型慢性荨麻疹患者的效果。方法:选取128 例血虚风燥型慢性荨麻疹患者,采用随机数字表法分为2 组,对照组给予盐酸西替利嗪片治疗,观察组给予益气疏风汤联合盐酸西替利嗪片治疗,2 组均连续治疗4 周。治疗前后评定2 组的症状严重程度评分[瘙痒、风团发作个数、最大风团直径、风团发作持续时间、风团外观及风团发作频次]、皮肤病生活质量指数(DLQI) 评分,检测CC 型趋化因子[单核细胞趋化因子-1(MCP-1)、受激活调节正常T 细胞表达和分泌因子(Rantes)、嗜酸性粒细胞趋化因子(Eotaxin)]、免疫球蛋白E(IgE) 及补体C3、C4 水平,统计2 组的临床疗效、不良反应发生情况和复发情况。结果:治疗4 周后,观察组临床疗效总有效率高于对照组(P<0.05)。2 组瘙痒、风团发作个数、最大风团直径、风团发作持续时间、风团外观及风团发作频次评分均较治疗前下降(P<0.05),观察组6 项荨麻疹严重程度评分均低于对照组(P<0.05)。2 组MCP-1、Rantes、Eotaxin 水平均较治疗前下降(P<0.05),观察组3 项指标值均低于对照组(P<0.05)。2 组补体C3、C4 水平均较治疗前上升(P<0.05),IgE 水平均较治疗前下降(P<0.05);观察组补体C3、C4 水平均高于对照组(P<0.05),IgE 水平低于对照组(P<0.05)。2 组DLQI 评分均较治疗前下降(P<0.05),观察组DLQI 评分低于对照组(P<0.05)。2 组不良反应发生率、复发率比较,差异均无统计学意义(P>0.05)。结论:益气疏风汤联合盐酸西替利嗪片治疗慢性荨麻疹可有效减轻症状,调节患者的免疫功能,提高疗效,改善生活质量。

    Abstract:

    Abstract: Objective: To observe the effect of Yiqi Shufeng tang combined with cetirizine hydrochloride tablets for patients with chronic urticaria of blood deficiency and wind- dryness type. Methods: A total of 128 cases of patients with chronic urticaria of blood deficiency and wind- dryness type were divided into two groups according to the random number table method. The control group was treated with cetirizine hydrochloride tablets,and the observation group was treated with Yiqi Shufeng tang combined with cetirizine hydrochloride tablets. Both groups were treated for four weeks. Before and after treatment,the symptom scores of severity including pruritus,number of wheal,maximum diameter of wheal,duration of wheal,appearance of wheal,and attack frequency of wheal,and the scores of Dermatology Life Quality Index(DLQI) in the two groups were evaluated. The levels of CC chemokines including monocyte chemoattractant protein-1(MCP-1),regulation on activation normal T-cell expressed and secreted(Rantes) and eosinophil chemokine(Eotaxin),immunoglobulin E(IgE),and complement C3 and C4 were detected. The clinical effects, incidences of adverse reactions and recurrences in the two groups were counted. Results:After four-week treatment,the total effective rate of clinical effect in the observation group was higher than that in the control group(P<0.05). The scores of pruritus,number of wheal,maximum diameter of wheal, duration of wheal,appearance of wheal,and attack frequency of wheal in the two groups were decreased when compared with those before treatment (P<0.05),and the above six scores of severity of urticaria in the observation group were lower than those in the control group (P<0.05). The levels of MCP-1,Rantes and Eotaxin in the two groups were decreased when compared with those before treatment (P<0.05),and the three levels in the observation group were lower than those in the control group(P<0.05). The levels of complement C3 and C4 in the two groups were increased when compared with those before treatment(P<0.05),and IgE levels were decreased(P<0.05);the levels of complement C3 and C4 in the observation group were higher than those in the control group(P<0.05),and IgE level was lower(P<0.05). The DLQI scores in the two groups were decreased when compared with those before treatment(P<0.05),and the DLQI score in the observation group was lower than that in the control group(P<0.05). There was no significant difference being found in the comparison of incidences of adverse reactions and recurrences between the two groups(P>0.05). Conclusion:Yiqi Shufeng tang combined with cetirizine hydrochloride tablets for chronic urticaria can effectively relieve symptoms, regulate immune function, and improve curative effect and quality of life.

    参考文献
    相似文献
    引证文献
引用本文

孟艳鲜.益气疏风汤联合盐酸西替利嗪片治疗慢性荨麻疹临床研究[J].新中医,2022,54(6):139-143

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-03-25
  • 出版日期: